RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: The aims of our study were to assess the correlation between serum HER2 and clinicopathologic factors, the effect of serum HER2 on survival rate, and the effect of changes in serum HER2 levels between pre- and post-adjuvant chemotherapy on survival rate. Methods: The study subjects, 200 women with breast cancer, were a subset of patients operated on between January 2005 and December 2006. We evaluated changes in serum HER2 levels between pre- and post-adjuvant chemotherapy. Results: Being estrogen receptor (ER) negative was also correlated with high serum HER2 (p=0.017). The number of patients with changes in serum HER2 (>20% increased level during the follow-up period) was correlated with advanced T-stage (p=0.010), advanced American Joint Committee on Cancer (AJCC) stage (p=0.015) and poor histologic grade (p=0.001). Univariate analysis for prognostic factors associated with disease-free survival (DFS) revealed that the difference in DFS between those with serum HER2 level <15 ng/mL and those with levels ≥15 ng/mL was statistically significant (p=0.0129) and the changes in serum HER2 levels were also statistically significant (p=0.001). Prognostic factors associated with overall survival revealed that the changes in serum HER2 levels between pre- and post-adjuvant chemotherapy were statistically significant (p=0.0012). Conclusion: Serum HER2 level is associated with a more advanced degree of axillary lymph node involvement and associated with ER negativity. And Changes in serum HER2 levels are associated with more advanced AJCC staging and histologic tumor grade. There are significant associations between serum HER2 level, changes in serum HER2 levels and 5-year DFS.

참고문헌 (Reference)

1 박래경, "전이성 유방암 환자에서 혈청 HER-2/neu 와 CA15-3의 상관성" 한국유방암학회 11 (11): 18-24, 2008

2 강선희, "유방암 환자에서 혈청 내 HER-2/neu 세포외 도메인의 측정에 대한 고찰: 조직학적 방법 및 임상병리학적 요인과의 연관성" 대한외과학회 78 (78): 271-276, 2010

3 이민혁, "건강한 한국여성에서의 혈청 HER-2/neu 참고치 설정" 한국유방암학회 9 (9): 301-308, 2006

4 Lennon S, "Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer" 27 : 1685-1693, 2009

5 Lafky JM, "Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole" 65 : 3059-3062, 2005

6 Hudelist G, "Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer" 42 : 186-192, 2006

7 Ali SM, "Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer" 48 : 1314-1320, 2002

8 Tsutsui S, "Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer" 71 : 67-75, 2002

9 Fehm T, "Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer" 24 : 1987-1992, 2004

10 Müller V, "Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer" 86 : 9-18, 2004